Abstract
In the quest for personalized medicine, only a few biological parameters are routinely used to select patients prior to the initiation of anticancer targeted therapies, including mTOR inhibitors. Identifying biological factors that may predict efficacy or resistance to mTOR inhibitors represents an important challenge since rapalogs may exert antitumor effects through multiple mechanisms of action. Despite the fact that no such a factor is currently available, several molecular patterns are emerging, correlating with sensitivity and/or resistance to rapalogs. While activation of the phosphatidylinositol 3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, overexpression of cyclin D1, and functional apoptosis seem to sensitize tumor cells to rapalogs, Bcl2 overexpression or KRAS mutations are reported to be associated with resistance to mTOR inhibitors in several preclinical models. Translational research aimed at validating those parameters in clinical trials is ongoing.
Similar content being viewed by others
References
Albert S, Serova M, Dreyer C et al (2010) New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs 19:919–930
Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5:671–688
Le Tourneau C, Faivre S, Serova M et al (2008) mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer 99:1197–1203
Faivre S, Raymond E (2008) Mechanism of action of rapalogues: the antiangiogenic hypothesis. Expert Opin Investig Drugs 17:1619–1621
O’Donnell A, Faivre S, Burris HA 3rd et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588–1595
Neshat MS, Mellinghoff IK, Tran C et al (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98:10314–10319
Noh WC, Mondesire WH, Peng J et al (2004) Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10:1013–1023
Grunwald V, DeGraffenried L, Russel D et al (2002) Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62:6141–6145
Hara S, Oya M, Mizuno R et al (2005) AKT activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an AKT inhibitor. Ann Oncol 16:928–933
Hay N (2005) The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8:179–183
Wang X, Yue P, Kim YA et al (2008) Enhancing mammalian target of rapamycin (mTOR)—targeted cancer therapy by preventing mTOR/Raptor inhibition-initiated, mTOR/Rictor-Independent Akt Activation. Cancer Res 68:7409–7418
Dibble CC, Manning BD (2009) A molecular link between AKT regulation and chemotherapeutic response. Cancer Cell 16:178–180
Fuchs BC, Fujii T, Dorfman JD et al (2008) Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to Epidermal Growth Factor receptor inhibition in human hepatoma cells. Cancer Res 68:2391–2399
Zhao L, Vogt PK (2008) Class I PI3K in oncogenic cellular transformation. Oncogene 27:5486–5496
Di Nicolantonio F et al (2010) Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 20:2858–2866
Witzig TE, Geyer SM, Ghobrial I et al (2005) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23:5347–5356
Hess G, Herbrecht R, Romaguera J et al (2009) Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27:3822–3829
Figlin RA, de Souza P, McDermott D et al (2009) Analysis of PTEN and HIF-1a and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-a. Cancer 115:3651–3660
Bae-Jump VL, Zhou C, Boggess JF et al (2010) Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment. Gynecol Oncol 119:579–585
Yu K, Toral-Barza L, Discafani C et al (2001) mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8:249–258
Yang L, Clarke MJ, Carlson BL et al (2008) PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clin Cancer Res 14:3993–4001
Raymond E, Alexandre J, Faivre S et al (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336–2347
Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281
Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513
Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523
Aguirre D et al (2004) Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis 9:797–805
Majumder PK, Febbo PG, Bikoff R et al (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10:594–601
Aissat N, Le Tourneau C, Ghoul A et al (2008) Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 62:305–313
Wangpaichitr M, Wu C, You M et al (2008) Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Eur J Pharmacol 591:124–127
Conflict of interest statement
No funds were received in support of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Delbaldo, C., Albert, S., Dreyer, C. et al. Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors. Targ Oncol 6, 119–124 (2011). https://doi.org/10.1007/s11523-011-0177-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11523-011-0177-6